There are currently no upcoming events.

Corporate Profile

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.

The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital... More >>

Recent News

More >>
Cardiovascular Systems Reports Fiscal 2011 First-Quarter Financial Results 11/03/10
Conference Call Scheduled for Today, November 3, 2010 at 3:45 PM CT (4:45 PM ET) ST. PAUL, Minn., Nov 03, 2010 (BUSINESS WIRE) - Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII): Financial performance improved significantly over prior year's first quarter Revenue increased 20 percent to $18.2 million Operating expenses remained consistent with prior-year levels Adjusted EBITDA loss improved 51 percent to $(1.7) million Net loss improved 31 percent to $(4.3) million, or $(0.28) per share Scientific evidence continues to build, with over 1,700 patients studied Over 33,000 patients have been treated to date Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal first quarter ended September 30, 2010. CSI's revenue in the first quarter rose to $18.2 million, a 20 percent gain over revenue of $15.2 million in the first...
More >>
Cardiovascular Systems Settles Employment Litigation 11/02/10
ST. PAUL, Minn., Nov 02, 2010 (BUSINESS WIRE) - Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), announced today that it has entered into a settlement agreement with ev3, Inc., now part of Covidien plc. The agreement dismisses all claims and counterclaims in the employment lawsuit between the two companies. The litigation stems from a suit ev3 originally filed against CSI in 2007 related to employees who joined CSI from ev3. Pursuant to the agreement, CSI will pay ev3 $1.0 million, in the form of $750,000 cash and a $250,000 promissory note, due by January 1, 2014. CSI will receive insurance proceeds of $500,000 related to the settlement. Neither party admits any liability or wrongdoing. "Reaching a settlement in this lawsuit is in the best interest of CSI," said David L. Martin, CSI president and chief executive officer. "By resolving this issue, we can move forward and focus on our business and growth opportunities, without the distractions and expense of prolonged litigation."...
More >>